Fake pharmaceuticals not only harm innovators, they can have tragic consequences, and require a robust response from the authorities. LSIPR assesses how officials, particularly in South America, are responding to the threat.
Most readers will know the effect that counterfeits can have on both a product and the wider public. Countless lawsuits will mention the “irreparable harm” caused to the company and to consumers who purchase said products. In the pharmaceutical industry in particular, these injuries can be fatal.
The true scale of the problem is not exactly known, as counterfeit drugs by their very nature are designed to be difficult to detect.
The World Health Organisation (WHO) stated as part of a factsheet in January 2016 that substandard, spurious, falsely labelled, falsified and counterfeit (SSFFC) medical products affect every nation in the world. It added that many countries and the media frequently report successful operations against manufacturers of SSFFC medical products.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
counterfeit pharmaceuticals, active pharmaceutical ingredients, south america customs, death, IMPI, IP, South American Drug Gangs, smuggling,